Public communications of EHDS stakeholder meeting with EU officials (6 Sep 2023)

Public communications of EHDS stakeholder meeting with EU officials (6 Sep 2023)

​6 September 2023, Brussels – OPTIMA, as part of a multi-stakeholder group consisting of 32 European patient organisations, medical associations, research organisations, data collaborations and industry associations met EU officials, including MEP Tomislav Sokol, Co-Rapporteur, as well as several permanent representations that will hold upcoming Presidencies of the Council of the European Union, to discuss how the European Health Data Space (EHDS) can facilitate health research and innovation to create tangible benefits for patients in the EU.

The meeting was held in follow-up to a joint statement issued by the group in June 2023 in which the organisations outlined the challenges of implementing an opt-out mechanism. In that statement, the group agreed that the Commission’s proposal strikes an adequate balance between delivering health-related benefits for patients in the EU and mitigating/eliminating any risks to their rights and interests.

The healthcare community remind that ensuring the trust of patients and other stakeholders in the healthcare system is vital. The group also call on legislators to adopt a consistent, EU-wide approach to unlock the potential value of using health-related data for research and innovation.

The 32 organisations raise their concerns that an opt-out or opt-in mechanism with regard to the secondary use of electronic health data under the EHDS may lead to health data disparities, where datasets underrepresent certain segments of the overall population. This would increase risks and undermine the reliability of data-driven health interventions. Instead of introducing more complexity, such as a general opt-out mechanism, more consideration should be given to ensure transparency and accountability regarding the processing operations performed on electronic health data and the results obtained from secondary use, and to the effectiveness of the safeguards in place.

Joint Statement: health organisations define EHDS’ opt-out required for life-saving research

Joint Statement: health organisations define EHDS’ opt-out required for life-saving research

On 6 June, OPTIMA joined together with 31 other health stakeholders to share views on specific recommendations for a potential opt-out mechanism in the future EHDS.

These organisations and initiatives have joined forces because they all share the view that health data are precious and renewable resources that can power decision-making for clinical care, deliver life-saving innovations, and strengthen health systems in the 21st century.

Discussions in the EU policy-making process now include proposals for an opt-out mechanism for citizens to withdraw their data from secondary use purposes (that is, from research, regulatory purposes and evidence based policy making). The original European Commission proposal did not include this mechanism.

The group of stakeholders support the approach taken in the Commission’s original legislative proposal from May 2022 as it strikes a sensible balance between protection of personal data while enabling the use of data for research and innovation to create tangible benefits for patients and citizens. The stakeholders raise concerns about the real risk that data bias will form part of the EHDS from its inception and thus undermine its principal value for secondary use research purposes if an opt-out or opt-in mechanism is approved, and call for an impact assessment that will inform implementation of this policy option.

If the proposals for opt-out are approved in the final EHDS legislation, the group make six recommendations. They believe the opt-out mechanism should:

  • be applicable across all Health Data Access Bodies in EU Member States, limiting the scope of national derogation and ensuring that the technical specifications are aligned.
  • consider the impact on health and care professionals and for other data holders.
  • be capable of implementation across the EU, without limiting lawful and ethical data sharing for secondary purposes.
  • be routinely monitored as part of a regularly updated HealthData@EU data governance framework.
  • have a limited, but well-defined, consistent and transparent scope.
  • have necessary investment, infrastructure and budget to ensure sufficient transparency so that citizens are well informed of the opt-out.

Finally, the current debate on enabling secondary use of health data in Europe highlights the need to achieve stakeholder alignment where possible on the implementation journey ahead for the EHDS. It also speaks to the need for implementation decisions to be highly informed by those with experience and responsibilities for on-the-ground implementation. This reiterates a need for strong, balanced and inclusive stakeholder representation within the governance model of the EHDS such as its Board of Directors.

Click here for the full statement.

 

Stakeholders’ consensus response to the proposed European Health Data Space

Stakeholders’ consensus response to the proposed European Health Data Space

On 20 October, OPTIMA joined a group of 29 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.

The stakeholders, which include medical professional and research organisations, patient representatives, industry associations and data collaborations strongly support the aims of the EHDS as proposed by the European Commission. We believe the adoption of the new legislation “can bring important European alignment to, and rapidly scale up, well-governed access to health data sets for the delivery of healthcare services but also for a wide range of secondary use purposes for better health outcomes.”  

The consensus statement encourages decision-makers to strongly support this Regulation and to engage with stakeholders to ensure the final Regulation optimises its potential. The statement also formulates several recommendations to consider when developing the more specific implementation plans to put this Regulation into practice across the Member States:

  1. A broad range of stakeholders must be strongly involved from the outset of the process to guarantee the success of the EHDS.
  2. The EHDS must align with all relevant horizontal and sectoral European laws.
  3. There must be harmonised interpretation and implementation of the Regulation across the EU.
  4. Approvals for secondary use of health data must be consistent and harmonised across Europe.
  5. The scope of EHR systems must be defined clearly within the Regulation.
  6. The successful implementation of the EHDS must be adequately resourced.
  7. Existing health data infrastructures must be leveraged to allow continuity and build on existing expertise.

Will the European Health Data Space unleash the power of data?

Will the European Health Data Space unleash the power of data?

OPTIMA coordinator Prof. James N’Dow (WP1 lead, WP9 lead) and Sarah Collen (WP8 member) co-chair the Health Data Sharing Taskforce of the Biomed Alliance. On 14 December, the Alliance released a new statement ahead of the upcoming European Commission legislative proposal on the European Health Data Space (EHDS). The new EHDS can play a key role in facilitating health data sharing for healthcare provision, health research and policy making if certain key aspects are taken into account. The EAU has much relevant experience to offer from leading two international Big Data consortiums funded by the EU Innovative Medicines Initiative (IMI) and experience with EAU Research Foundation experience with patient registries and clinical trials.  OPTIMA’s goal is to design, develop and deliver the first interoperable, GDPR-compliant real-world oncology data and evidence generation platform in Europe, to potentially advance treatment for patients with solid tumours in the three cancers. 

The BioMed Alliance Task Force on Health Data Sharing, in close cooperation with the European Association of Urology (EAU) and the European Organisation for Research and Treatment of Cancer (EORTC) have therefore proposed a set of recommendations for the governance, implementation and incentivisation of adoption of the EHDS. 

The statement particularly highlights the need to involve a broad range of stakeholders and to align different legislative approaches with a clear and enabling EU legal framework which will give legal clarity to researchers.

Read the full statement here.

 

Will the European Health Data Space unleash the power of data?

Tackling Cancer through Real World Data
and Artificial Intelligence